Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Wellness Focus Cayman Islands.
Press releases published on June 25, 2025
Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements
GlobeNewswire
·
June 25, 2025
DOVER, Del., June 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”), announced today that on June 24, 2025 …
NASM Tackles Modern Stress and Long-Term Resilience with New Mindfulness-Based Wellness Course
GlobeNewswire
·
June 25, 2025
Gilbert, Arizona, June 25, 2025 (GLOBE NEWSWIRE) -- The National Academy of Sports Medicine® (NASM), the global leader in fitness and wellness education, training, and certifications, is thrilled to announce the launch of its new Mindful Stress Management …
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit
GlobeNewswire
·
June 25, 2025
WARREN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and …
Indaptus Therapeutics Announces Reverse Stock Split
GlobeNewswire
·
June 25, 2025
NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its …
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan
GlobeNewswire
·
June 25, 2025
PRINCETON, N.J., and TOKYO, June 25, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) for the …
SmartVascular Dx™ Test: Enhancing Vascular Care in the Midwest
GlobeNewswire
·
June 25, 2025
IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., (“MSL” or “the Company”), is a leading developer of precision diagnostic tests that address unmet clinical needs, is proud to announce its expansion in the Midwest with the …
First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial
GlobeNewswire
·
June 25, 2025
The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve …
Global Juice Testing Industry on Track for Robust 8.2% CAGR Growth | Europe Leads the Way in Juice Testing Standards and Compliance
GlobeNewswire
·
June 25, 2025
Delray Beach, FL, June 25, 2025 (GLOBE NEWSWIRE) -- The juice testing market size is on an upward trajectory, expected to rise from USD 0.86 billion in 2025 to USD 1.28 billion by 2030, at a CAGR of 8.2%. This growth is fueled by rising health awareness, …
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
GlobeNewswire
·
June 25, 2025
REYKJAVIK, Iceland and PISCATAWAY, N.J. and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC …
Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director
GlobeNewswire
·
June 25, 2025
Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director Egham, UK – 25 June 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company developing and delivering medicines for patients …
Actimed Therapeutics Enrolls First Patients in Phase 2a PROACT Study Programme to Assess S-pindolol benzoate in Obese Patients During and Post-GLP-1 Agonist Therapy
GlobeNewswire
·
June 25, 2025
Two-part clinical study programme to evaluate change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst 1) receiving the GLP-1 agonist semaglutide; and 2) after cessation of semaglutide treatment Initial proof-of- …
Führendes Unternehmen für Access Management für das Gesundheitswesen und andere kritischen Branchen verstärkt Engagement in Deutschland, Österreich und der Schweiz
GlobeNewswire
·
June 25, 2025
LANGENFELD, Deutschland, June 25, 2025 (GLOBE NEWSWIRE) -- Mit der Besetzung von zwei neuen Stellen unterstreicht Imprivata, das führende Unternehmen für Access Management im Gesundheitswesen und anderen kritischen Branchen, sein Engagement in Deutschland, …
LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park
GlobeNewswire
·
June 25, 2025
LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park London, 25 June 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today …
OSE Immunotherapeutics provides an update on ongoing proceedings
GlobeNewswire
·
June 25, 2025
OSE Immunotherapeutics provides an update on ongoing proceedings Nantes, June 25th, 2025, 8:00 a.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), announces that, following the hearing on June 24th, 2025, regarding the request to retract the …
OSE Immunotherapeutics met à jour l’information sur les procédures en cours
GlobeNewswire
·
June 25, 2025
OSE Immunotherapeutics met à jour l’information sur les procédures en cours NANTES, France, 25 juin 2025, 8 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) annonce qu’à la suite de l’audience le mardi 24 juin 2025, relative à la demande …
Addex Shareholders Approve All Resolutions at Annual General Meeting
GlobeNewswire
·
June 25, 2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today …
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
GlobeNewswire
·
June 25, 2025
Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active antibody-mediated rejection in kidney …
Communiqué de presse : Le riliprubart est désigné comme médicament orphelin aux États-Unis pour le rejet induit par les anticorps dans la transplantation d’organes solides
GlobeNewswire
·
June 25, 2025
Le riliprubart est désigné comme médicament orphelin aux États-Unis pour le rejet induit par les anticorps dans la transplantation d’organes solides Étude de phase 2 en cours évaluant le riliprubart pour la prévention et le traitement potentiels du rejet …
Tilray Medical erhält vom italienischen Gesundheitsministerium die erste Genehmigung für den Vertrieb von medizinischen Cannabisblüten für therapeutische Zwecke
GlobeNewswire
·
June 25, 2025
SAVONA, Italien, June 25, 2025 (GLOBE NEWSWIRE) -- Tilray Medical („Tilray“), ein Geschäftsbereich von Tilray Brands, Inc. (NASDAQ: TLRY und TSX: TLRY) und weltweit führender Anbieter von medizinischem Cannabis, der die therapeutische Zusammenarbeit …
Une première autorisation de distribution de la fleur de cannabis médicinal à des fins thérapeutiques délivrée par le ministère de la Santé italien pour Tilray Medical
GlobeNewswire
·
June 25, 2025
SAVONE, Italie, 25 juin 2025 (GLOBE NEWSWIRE) -- Tilray Medical, ci-après « Tilray », une division de Tilray Brands, Inc. (NASDAQ : TLRY et TSX : TLRY) et un leader mondial du cannabis thérapeutique permettant aux patients comme aux professionnels de santé …